Semaglutide, the active ingredient in Ozempic and Wegovy, appeared to reduce the risk of Alzheimer’s disease in people with ...

The active ingredient found in popular medications for Type 2 diabetes and weight loss, including Ozempic and Wegovy, may ...

Prime Therapeutics reviewed pharmacy and medical claims data for 3,046 people with commercial health plans that cover GLP-1 ...

The active ingredient in Ozempic was associated with a 40% to 70% lower risk of a first-time Alzheimer’s diagnosis in ...

Add Alzheimer’s disease to the list of conditions that might benefit from the revolutionary diabetes drug Ozempic, a ...

Nearly 7 million Americans 65 and older are living with Alzheimer’s disease, which gradually destroys memory and thinking ...

The full-year cost of care for U.S. patients with obesity two years after starting on Novo Nordisk’s Wegovy or similar GLP-1 ...

Drugs like Wegovy may trim your waistline but not medical costs, according to an analysis of U.S. health insurance claims ...

Under US law, compounding pharmacies can make and sell patent-protected drugs that are on the FDA's shortages list in limited ...

Novo Nordisk and Eli Lilly still have first-mover advantage, but Roche, Pfizer and others all have similar products in the ...

Novo Nordisk is suing to block compounding pharmacies from producing cheaper versions of its medications, Ozempic and Wegovy.

Novo Nordisk (NYSE:NVO) has appealed to the U.S. Food and Drug Administration (FDA) to halt the production of compounded ...